<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646058</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC-N/2017/FJ-01</org_study_id>
    <nct_id>NCT03646058</nct_id>
  </id_info>
  <brief_title>Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode</brief_title>
  <acronym>BUPRIS</acronym>
  <official_title>Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at investigating if adjunctive buprenorphine at low dose to treatment as
      usual is effective in reducing severe suicidal ideas in major depressive episode, and at
      determining the most effective dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized to two doses of buprenorphine (0.4mg and 0.8mg) or placebo.
      The duration of treatment will be 21 days with 7 days withdrawal period. Two follow-up phone
      calls at 3 and 6 months will investigate occurence of suicidal behavior.

      The main outcome will be changes in suicidal ideas levels during the first week.

      Secondary outcomes will be changes in suicidal ideas during the following 21 days, changes in
      depression and psychological pain levels over the first 28 days, dropout rates, reasons and
      occurence of side effects over the first 28 days, withdrawal symptoms dung the withdrawal
      period, changes in neuropsychological and neuroimaging measures between Day 0 and Day 28.

      Blood and stool samples will be collected at 4 time points and stored in a biobank for future
      analyses.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Beck Scale for Suicidal Ideation (SSI) scores from Day 0 to 7</measure>
    <time_frame>7 days</time_frame>
    <description>Clinician-based questionnaire measuring level of suicidal ideas over the last 7 days; 21 items scored 0 to 2; total score ranges from 0 to 38 (last 2 items not counted), higher scores mean more intense suicidal ideas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Beck Scale for Suicidal Ideation (SSI) scores</measure>
    <time_frame>Day 8 to day 28</time_frame>
    <description>Clinician-based questionnaire measuring level of suicidal ideas over the last 7 days; 21 items scored 0 to 2; total score ranges from 0 to 38 (last 2 items not counted); higher scores mean more intense suicidal ideas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Beck Depression Inventory II (BDI-II) scores from Day 0 to 28</measure>
    <time_frame>28 days</time_frame>
    <description>Self questionnaire measuring depression level over the last 7 days; 13 items scored 0 to 3, with the total score ranging from 0 to 39; higher scores mean higher level of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Montgomery-Asberg Depression Rating Scale (MADRS) from Day 0 to 28</measure>
    <time_frame>28 days</time_frame>
    <description>Clinician-based questionnaire measuring the level of depression of the last 7 days; 10 items score 0 to 6, with the total scores ranging fron 0 to 60; Higher scores mean higher level of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Physical and Psychological Pain - Visual Analog Scale (PPP-VAS) scores from Day 0 to 28</measure>
    <time_frame>28 days</time_frame>
    <description>Visual Analog Scale measuring physical then psychological pain over 3 periods each (current, worst over the last 7 days, mean over the last 7 days); 6 dimensions in total; each dimension is scored from 0 (no pain) to 10 (maximal pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for discontinuing treatment over the first 28 days</measure>
    <time_frame>28 days</time_frame>
    <description>Patient's self-report; measurement will be the overall (over 28 days) incidence for each event reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects over the first 28 days</measure>
    <time_frame>28 days</time_frame>
    <description>Patient's self-report; measurement will be the overall (over 28 days) incidence for each event reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal symptoms</measure>
    <time_frame>Day 22 to day 28</time_frame>
    <description>Patient's self-report; measurement will be the incidence of any withdrawal symptom during the withdrawal phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of a suicide attempt during the whole study</measure>
    <time_frame>180 days</time_frame>
    <description>Interview based; measurement will be the incidence of any suicide attempt between Day 0 and 28, between Day 29 and 90, and between Day 90 and 180.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Iowa Gambling Task (IGT) scores between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Computerized test measuring decision-making; scores are the difference between advantageous and disadvantageous choices; scores range from -100 to + 100, higher scores means better performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in modified Stroop test scores between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Classical Stroop test modified with suicide-related words to measure specific attention bias; scores are the number of errors and total reaction time; higher scores mean worse performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in verbal fluency test scores between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Classical test measuring verbal fluency skills for semantic and phonological categories; Patients are instructed to give as many words as possible for a given category then for words starting with a given letter, within a 1 minute time frame; Scores are the number of correct words; higher scores mean higher performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in N-Back test scores between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Classical test of working memory using letters; scores are the number of words correctly identified for each level of recall (0 to 2 back); higher scores mean better performance; also, the number of omission and commission errors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Go/No-Go test between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Classical test of cognitive inhibition, letter version; scores are the number of omission and commission errors (higher scores mean worse performance) and reaction times (higher scores mean better performance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Trail Making Test (TMT) scores between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Classical test of planning abilities; scores are the difference between the time to complete parts B and A of the test; Higher scores mean worse performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Implicit Association Test (IAT) scores between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>IAT version adapted for suicide/death; scores are the measure of reaction times in the association between suicide/death words and me/myself words; lower scores mean higher association.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Magnetic Resonance Imaging (MRI) T1 measures between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Brain structural MRI-T1 sequence measured at Day 0 and Day 28 (5 minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Magnetic Resonance Imaging (MRI) T2 measures between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Brain structural MRI-T2 sequence measured at Day 0 and Day 28 (5 minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Magnetic Resonance Imaging (MRI) Diffusion Tensor Imaging (DTI) measures between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Brain Diffusion Tensor Imaging (DTI) sequence measured at Day 0 and Day 28 (20 minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Magnetic Resonance Imaging (MRI) Resting State (RS) measures between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Brain functional Resting State (RS) sequence measured at Day 0 and Day 28 (15 minutes)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Suicidal Ideation</condition>
  <condition>Major Depressive Episode</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo pills sublingual during 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.4mg buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 21 days, then 2 placebo pills per day for 1 week, all sublingual.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.8mg buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 3 days, then 2 pills of 0.4mg buprenorphine per day for 18 days, then 1 pill of 0.4 mg + 1 placebo pill per day for 3 days, then 2 placebo pills per day for 4 days, all sublingual.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Buprenorphine, 0.4mg pills, sublingual</description>
    <arm_group_label>0.4mg buprenorphine</arm_group_label>
    <arm_group_label>0.8mg buprenorphine</arm_group_label>
    <other_name>Temgesic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pills, sublingual, specifically made to mimick buprenorphine pills</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has been correctly informed.

          -  The patient must have given his/her informed and signed the consent form.

          -  The patient must be insured or beneficiary of a health insurance plan.

          -  The patient is at least 18 years old and 65 years old at the most.

          -  The patient is hospitalized or followed in consultation.

          -  The patient has a current major depressive episode without psychotic features
             according to the criteria of the &quot;Diagnostic and Statistical Manual of Mental
             Disorders&quot;

          -  The patient has a score &gt; 20 of the &quot;Montgomery-Asberg Depression Rating Scale&quot;.

          -  The patient has a current Scale for Suicidal Ideation (SSI) score &gt; 8.

        Exclusion Criteria:

          -  The patient is participating in another interventional trial;

          -  The patient is in an exclusion period determined by a previous study;

          -  The patient is under judicial protection, or is an adult under guardianship;

          -  The patient is under compulsory admission;

          -  The patient refuses to sign the consent;

          -  it is impossible to correctly inform the patient.

          -  The patient is pregnant or breastfeeding.

          -  The patient suffers from schizophrenia;

          -  The patient has a lifetime history of substance use disorder (except tobacco and
             caffeine), moderate to severe, according to criteria of the &quot;Diagnostic and
             Statistical Manual of Mental Disorders&quot;;

          -  The patient currently suffers from severe and/or unstable medical condition (including
             severe respiratory or hepatic insufficiency) or a painful medical condition;

          -  The patient has a current known sleep apnea.

          -  The patient currently takes analgesic treatment (including Nonsteroidal
             anti-inflammatory drug and paracetamol);

          -  The patient currently takes central nervous depressant drugs at sedative doses (based
             on the investigator's assessment), including benzodiazepines, antihistamines, and
             sedative antipsychotics;

          -  The patient currently takes major CYP3A4 Inhibitors and inducers;

          -  The patient currently takes has received Electroconvulsivotherapy over the last 3
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice Jollant, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Sainte-Anne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice Jollant, MD</last_name>
    <phone>+33(0)1 45 65 85 72</phone>
    <email>fabrice.jollant@parisdescartes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU Hôpital Saint-Jacques</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuel Haffen, MD</last_name>
      <phone>+33(0)3 81 21 81 54</phone>
      <email>emmanuel.haffen@univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>Djamila Bennabi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mircea Polosan, MD</last_name>
      <phone>+33(0)4 76 76 87 10</phone>
      <email>MPolosan@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuelle Corruble, MD</last_name>
      <phone>+33(0)1 45 21 25 24</phone>
      <email>emmanuelle.corruble@bct.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuel Poulet, MD</last_name>
      <phone>+33(0)4 72 11 00 09</phone>
      <email>emmanuel.poulet@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Charlotte Brevet-Aeby, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clémence Bied, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine Ragonnet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe Courtet, MD</last_name>
      <phone>+33(0)4 67 33 85 81</phone>
      <email>p-courtet@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Emilie Olié, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAPPA Jacques PREVERT</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Sauvaget, MD</last_name>
      <phone>+33(0)2.40.08.47.95</phone>
      <email>anne.sauvaget@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Les Sophoras</name>
      <address>
        <city>Nîmes</city>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stéphane Torres, MD</last_name>
      <phone>+33(0)4 66 62 79 00</phone>
      <email>stmx@free.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume Collin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mocrane Abbar, MD</last_name>
      <phone>+33 (0)4.66.68.42.36</phone>
      <email>m-abbar@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Jorge Lopez Castroman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ismaël Conegero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Sainte-Anne</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabrice Jollant, MD</last_name>
      <phone>+33 (0)1 45 55 65 92</phone>
      <email>fabrice.jollant@parisdescartes.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Roy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume Pineau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yann Mongin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philip Gorwood, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Henri Laborit</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nemat Jaafari, MD</last_name>
      <phone>+33(0)5 16 52 61 18</phone>
      <email>nemat.jaafari@ch-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37540</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Wissam El-Hage, MD</last_name>
      <phone>+33(0)2 47 47 80 43</phone>
      <email>wissam.elhage@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu Lemaire, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>Suicidal ideas</keyword>
  <keyword>Depression</keyword>
  <keyword>Buprenorphine</keyword>
  <keyword>Opioid agonist</keyword>
  <keyword>Mental pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suicidal Ideation</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

